OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
KDH$84.0057

Thonburi Medical Centre PCL

Healthcare Facilities & ServicesVerified

Thonburi Medical Centre PCL maintains a strong liquidity position, with a current ratio of 4.43 and cash and equivalents amounting to 249.35 million THB, indicating a robust ability to meet short-term obligations. The company's liquidity is further supported by a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing and a conservative capital structure. In terms of profitability, the company's return on equity (ROE) of 4.29% and return on assets (ROA) of 3.41% are below the industry median for healthcare facilities and services, which typically report ROE and ROA in the 6-8% and 4-5% ranges, respectively. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of a regional downturn or regulatory change. Looking ahead, the company's revenue is projected to grow at a modest pace, with the current fiscal year expected to show a slight increase in revenue compared to the previous year. However, the growth trajectory is not expected to accelerate significantly in the next fiscal year, as the company's capital expenditure remains negative at -11.18 million THB, indicating a focus on cost management rather than expansion. The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is further supported by the absence of significant share issuance activity in the recent financial statements. However, the company's price-to-earnings ratio of 51.67 and price-to-book ratio of 2.22 suggest that the stock is currently trading at a premium relative to its earnings and book value, which may indicate investor optimism or overvaluation. Recent events, including the latest financial filings and transcripts, do not indicate any material changes in the company's operations or strategic direction. The company continues to focus on maintaining its financial stability and operational efficiency, as reflected in its conservative capital structure and strong liquidity position.

30-day price · KDH+1.50 (+1.8%)
Low$81.50High$84.00Close$83.00As of4 Jun, 00:00 UTC
Profile
CompanyThonburi Medical Centre PCL
TickerKDH.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Thonburi Medical Centre PCL operates as a healthcare provider in the healthcare facilities and services industry, generating revenue primarily through medical services and patient care.

Classification. Thonburi Medical Centre PCL is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

Thonburi Medical Centre PCL maintains a strong liquidity position, with a current ratio of 4.43 and cash and equivalents amounting to 249.35 million THB, indicating a robust ability to meet short-term obligations. The company's liquidity is further supported by a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing and a conservative capital structure. In terms of profitability, the company's return on equity (ROE) of 4.29% and return on assets (ROA) of 3.41% are below the industry median for healthcare facilities and services, which typically report ROE and ROA in the 6-8% and 4-5% ranges, respectively. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of a regional downturn or regulatory change. Looking ahead, the company's revenue is projected to grow at a modest pace, with the current fiscal year expected to show a slight increase in revenue compared to the previous year. However, the growth trajectory is not expected to accelerate significantly in the next fiscal year, as the company's capital expenditure remains negative at -11.18 million THB, indicating a focus on cost management rather than expansion. The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is further supported by the absence of significant share issuance activity in the recent financial statements. However, the company's price-to-earnings ratio of 51.67 and price-to-book ratio of 2.22 suggest that the stock is currently trading at a premium relative to its earnings and book value, which may indicate investor optimism or overvaluation. Recent events, including the latest financial filings and transcripts, do not indicate any material changes in the company's operations or strategic direction. The company continues to focus on maintaining its financial stability and operational efficiency, as reflected in its conservative capital structure and strong liquidity position.
Key takeaways
  • Thonburi Medical Centre PCL has a strong liquidity position with a current ratio of 4.43 and low debt-to-equity ratio of 0.01.
  • The company's ROE and ROA are below industry medians, indicating underperformance in capital efficiency and asset utilization.
  • Revenue is concentrated in a single business segment with no material geographic diversification.
  • The company's revenue growth is expected to remain modest, with a focus on cost management rather than expansion.
  • The stock is trading at a premium with a P/E ratio of 51.67 and P/B ratio of 2.22.
  • The company's risk profile is low, with no immediate liquidity or dilution flags detected.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$246.3M
Gross profit$85.9M
Operating income$37.3M
Net income$31.5M
R&D
SG&A
D&A
SBC
Operating cash flow$101.1M
CapEx-$11.2M
Free cash flow$35.4M
Total assets$923.4M
Total liabilities$188.5M
Total equity$734.9M
Cash & equivalents$249.3M
Long-term debt$9.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$751.5M$47.8M$37.7M$104.3M
FY-3$1.06B$102.6M$81.0M$110.1M
FY-2$1.18B$128.3M$105.6M$101.5M
FY-1$1.02B$167.6M$140.6M$96.4M
FY0$1.14B$183.3M$152.2M$72.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$652.7M$507.5M$178.3M
FY-3$803.0M$613.7M$168.2M
FY-2$877.3M$704.7M$160.4M
FY-1$1.02B$802.4M$149.9M
FY0$1.11B$905.1M$134.6M
PeriodOCFCapExFCFSBC
FY-4$144.3M-$7.7M$104.3M
FY-3$178.7M-$16.5M$110.1M
FY-2$111.2M-$30.8M$101.5M
FY-1$178.4M-$46.7M$96.4M
FY0$213.9M-$78.8M$72.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$246.3M$37.3M$31.5M$35.4M
FQ-6$272.7M$58.8M$48.2M$48.2M
FQ-5$257.8M$26.5M$23.4M$9.2M
FQ-4$264.7M$48.8M$40.6M$20.7M
FQ-3$284.2M$47.0M$39.3M$29.5M
FQ-2$305.0M$56.8M$46.6M$41.8M
FQ-1$281.6M$30.7M$25.7M$29.0M
FQ0$277.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$923.4M$734.9M$249.3M
FQ-6$963.3M$783.2M$279.5M
FQ-5$1.02B$802.4M$149.9M
FQ-4$1.04B$843.0M$178.0M
FQ-3$1.04B$833.8M$163.9M
FQ-2$1.08B$880.5M$157.6M
FQ-1$1.11B$905.1M$134.6M
FQ0$952.0M$236.6M
PeriodOCFCapExFCFSBC
FQ-7$101.1M-$11.2M$35.4M
FQ-6$142.7M-$21.6M$48.2M
FQ-5$178.4M-$46.7M$9.2M
FQ-4$59.9M-$30.4M$20.7M
FQ-3$116.4M-$51.7M$29.5M
FQ-2$161.5M-$69.0M$41.8M
FQ-1$213.9M-$78.8M$29.0M
FQ0$46.1M-$13.1M
Valuation
Market price$84.00
Market cap$1.63B
Enterprise value$1.39B
P/E51.7
Reported non-GAAP P/E
EV/Revenue5.6
EV/Op income37.2
EV/OCF13.7
P/B2.2
P/Tangible book2.2
Tangible book$734.9M
Net cash$240.1M
Current ratio4.4
Debt/Equity0.0
ROA3.4%
ROE4.3%
Cash conversion3.2%
CapEx/Revenue-4.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricKDHActivity
Op margin15.2%5.6% medp25 -4.2% · p75 12.6%top quartile
Net margin12.8%2.8% medp25 -3.4% · p75 8.8%top quartile
Gross margin34.9%36.5% medp25 23.7% · p75 65.2%below median
CapEx / revenue-4.5%-4.9% medp25 -11.5% · p75 -2.0%above median
Debt / equity1.0%69.3% medp25 7.9% · p75 120.9%bottom quartile
Observations
IR observations
Last actual EPS-0.46 THB
Last actual revenue688,358,000 THB
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-13 00:10 UTC#4f37fddb
Market quoteclose THB 84.00 · shares 0.02B diluted
no public URL
2026-05-10 02:00 UTC#beee172d
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 07:37 UTCJob: 6ab132a3